Amongst other projects, our lab works within 3 groups, funded by the National Institute of Allergy and Infectious Diseases (NIAID):
- The National Institutes of Health: the Inner-City Asthma Consortium (ICAC)
- The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC)
- The Immune Tolerance Network (ITN)
- the Allergic Diseases Cooperative Research Centers
In studies with these collaborators, we use network analysis techniques such as cell-deconvolution and modular analysis to reduce the dimensionality of complex data, while simultaneously focusing on the salient elements of the immune response (Chaussabel, Baldwin 2014; Obermoster et al 2013; Li et al 2014). Collaborations like these help understand complex diseases while laying the groundwork for the discovery of new treatment approaches.
Genome transcriptional profiling and genome sequencing technologies are powerful approaches to identify novel biomarkers and mechanisms of immune mediated diseases. These technologies generate huge amounts of biological information and require sophisticated computational tools to understand molecular pathways of the immune system in health and disease.
Much of the lab's work focuses on molecular profiling of human respiratory samples collected during flares of disease, such as asthma exacerbations, respiratory infections, and allergic reactions. Furthermore, the group's work seeks to both develop and understand personalized approaches to the use of immune based therapeutics in these diseases.
Matt Altman, MD, MPhil
Naresh Doni Jayavelu
Dr. Altman's Interview at AAAAI
Big Data Reveals Surprising Defense Against COVID-19
Immunology to Change Lives: Where We're Going in 2023
BRI was formed with a clear plan: First, answer key fundamental questions about the immune system. Then, build on those answers to change lives. This is a very exciting time because we’re reaching that second stage of the plan.
$11.4 Million to Explore Link Between Viruses and Immune System Diseases
Understanding how viruses impact the immune system has long been a focus at BRI. Two years of pandemic life have made answering two questions particularly important: Can respiratory viruses like the common cold or COVID-19 start the chain reaction that leads to immune system disease?